Our Team

Dr. Weickert has been developing drugs, devices and startup companies for 29 years, many in the anti-infective therapeutic area. He has co-founded and/or led startups as CEO of Pacylex Pharmaceuticals, illumiSonics, Sonescence, and SEA Medical Systems, CBO of Strategent Life Sciences, Corium, and Therashock, COO of Greenfire Bio and Ohm Oncology, VP of development at SciDose and Auspex. At startups, he raised Seed through Series C capital and established partnerships worth more than $180 Million. He has extensive experience developing anti-infectives, as CEO of Sonescence, a Phase 2 stage drug delivery startup addressing skin and soft tissue infections including involving MRSA, as Senior Program Executive at Nektar where he set up an anti-infectives business unit and directed the flagship anti-infective product from inception through Phase 2, as CBO of Therashock developing a new theory and therapy for sepsis, and as an advisor or consultant for companies like Pulmatrix, Taris, and Lightline. Michael has prepared over 40 business plans including for the Nobel Prize winner Dr. Luc Montagnier and has driven product development from pre-clinical through Phase III/NDA. He obtained Orphan Drug and Fast Track designations for anti-infective products in the US and EU. Prior to joining the pharmaceutical industry, he was at the National Cancer Institute at NIH. He received his Ph.D. in Genetics from the University of Wisconsin.

Dr. Heaton brings a 30-year career in pharmaceutical discovery, development, and translational studies. He serves as CSO to the Cure JM Foundation, and most recently served as the CEO and President of Heaton-Brown Life Sciences and Novogen North America. Dr. Heaton, ushered several oncology compounds from the laboratory through Phase I, II and III clinical trials. He was also a board member at joint venture start-up with Yale, CanTx. Dr. Heaton is the senior author on over 100, globally granted-patents, covering a wide range of molecular architectures and diseases and has published multiple papers in peer-reviewed scientific journals. Dr. Heaton received his doctorate from James Cook University of North Queensland, his MBA from Melbourne Business School, and completed a sabbatical at Imperial College, London.

Dr. Holbein has over 35 years of experience: first as an infectious disease expert with Defense Canada, then Associate Professor in Medicine at McGill University, and finally, a technology developer commercializing life sciences biotechnologies in Canada, the EU and Australia. Bruce pioneered research on the roles of iron in bacterial infection and host defenses, designed DIBI, co-founded Chelation Partners, and initiated and managed the various collaborative proof-of–concept studies on DIBI.

Bruce is also an Adjunct Professor at Dalhousie University. He has a Ph.D. in microbiology/ biochemistry from the University of Guelph and has more than 100 scientific publications and 25 industrial patents.

Bob Miller is a Partner at CFOs2GO and co-Lead of their Healthcare and Life Science business. Bob served as CFO and sometimes COO for two decades, developing deep experience in raising funds and commercializing technologies. He deals with the complex integration of the regulatory, clinical, reimbursement, manufacturing, sales and marketing requirements for launching medical products and quickly growing revenue. He was CFO of GAF Corporation and Treasurer of Mead Corporation, both multi-billion-dollar companies. Having lost his mother to cancer early in life, he recognized how making treatments available could help people and families live more fulfilling lives. He now focuses on funding and commercializing unique and effective medical technologies. Bob earned his degree in economics and industrial engineering from Stanford and received his MBA from Columbia.

Dr. Ang has over 10 years’ experience in synthetic chemistry. Since 2016, Trisha has been the lead research chemist and directly involved with the synthetic aspects for streamlining the DIBI polymer process for cGMP industrial-scale production. Her work improved the yield and safety profile of the synthesis of DIBI’s critical metal chelating monomer leading to an unprecedented 74% process improvement by developing a two-step synthesis from originally five steps. Dr. Ang is co-inventor to a corresponding 2017 patent (WO2018035613A1). Trisha has also been project manager at Chelation Partners Inc. and on other independent research projects. Dr. Ang earned a master’s degree at the University of Toronto and received her Ph.D. degree in chemistry at Queen’s University.